A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis

Inclusion Criteria : 1. Voluntarily sign informed consent forms before any investigational procedure(s) are performed. 2. Male or female aged between 18 and 75 years at the time of signing the informed consent. 3. Clinical diagnosis of PN by a dermatologist for at least 3 months before the Screening visit. 4. At least 20 pruriginous lesions on the entire body with a bilateral distribution (on both legs, and/or both arms and/or trunk) at both screening and the baseline (Day 1) visits. 5. PP NRS score ≥ 7 at both screening and the baseline (Day 1) visits. 6. IGA-CPG-S score ≥ 3 at both the scre…